Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.42 |
| ▸ | CNR2 | P34972 | 3/20 | 0.41 |
| ▸ | SERPINE1 | P05121 | 2/20 | 0.40 |
| ▸ | ALB | P02768 | 1/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.37 |
| ▸ | NPC1 | O15118 | 1/20 | 0.37 |
| ▸ | LMNA | P02545 | 1/20 | 0.37 |
| ▸ | HTT | P42858 | 1/20 | 0.37 |
| ▸ | RAB9A | P51151 | 1/20 | 0.37 |
| ▸ | NHERF1 | O14745 | 1/20 | 0.36 |
| ▸ | NR1H4 | Q96RI1 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6830705 | 0.85 | ALB (0.42) | RXFP1ALBKMT2AHTTNHERF1 | |
| SCHEMBL6834154 | 0.83 | KMT2A (0.49) | RXFP1SERPINE1ALBMEN1KMT2A | |
| SCHEMBL6834472 | 0.83 | ALB (0.43) | RXFP1ALBNHERF1NR1H4 | |
| SCHEMBL6833137 | 0.82 | MAP3K5 (0.44) | RXFP1ALBKMT2ANHERF1NR1H4 | |
| SCHEMBL6862764 | 0.82 | MEN1 (0.37) | RXFP1CNR2MEN1KMT2ANPSR1 | |
| SCHEMBL6707720 | 0.82 | MEN1 (0.36) | RXFP1CNR2MEN1KMT2ANPSR1 | |
| SCHEMBL6834115 | 0.82 | ALB (0.47) | RXFP1SERPINE1ALBMEN1KMT2A | |
| SCHEMBL6835708 | 0.82 | CCKAR (0.51) | SMN1; SMN2NPC1LMNARAB9ANHERF1 | |
| SCHEMBL6833114 | 0.81 | ALB (0.42) | RXFP1ALBLMNANHERF1NR1H4 | |
| SCHEMBL6833687 | 0.81 | RXFP1 (0.43) | RXFP1ALBLMNANHERF1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040110802-A1 | Antibacterial benzoic acid derivatives | PHARMACIA & UPJOHN COMPANY | 2004-06-10 | — | — | US | claimed |
| US-20040110802-A1 | Antibacterial benzoic acid derivatives | PHARMACIA & UPJOHN COMPANY | 2004-06-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040110802-A1 | Antibacterial benzoic acid derivatives | GABRD, GABBR1, GABRA1 | RXFP1 3523/4885CNR2 3495/4885SERPINE1 1860/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.